Effects of Acetylcholine and Cholinergic Antagonists on the Activity of Nucleus of the Solitary Tract Neurons ⇑ Werner I

Total Page:16

File Type:pdf, Size:1020Kb

Effects of Acetylcholine and Cholinergic Antagonists on the Activity of Nucleus of the Solitary Tract Neurons ⇑ Werner I Brain Research 1659 (2017) 136–141 Contents lists available at ScienceDirect Brain Research journal homepage: www.elsevier.com/locate/bres Research report Effects of acetylcholine and cholinergic antagonists on the activity of nucleus of the solitary tract neurons ⇑ Werner I. Furuya a, Eduardo Colombari a, Alastair V. Ferguson b,1, Débora S.A. Colombari a,1, a Department of Physiology and Pathology, School of Dentistry, São Paulo State University, Araraquara, SP, Brazil b Department of Biomedical and Molecular Sciences, School of Medicine, Queen’s University, Kingston, ON, Canada article info abstract Article history: Previously we have demonstrated that microinjection of acetylcholine (ACh) into the intermediate Received 3 August 2016 nucleus of the solitary tract (iNTS) induced sympatho-inhibition combined with a decrease in the phrenic Received in revised form 11 January 2017 nerve activity (PNA), whereas in the commissural NTS (cNTS), ACh did not change sympathetic nerve Accepted 21 January 2017 activity (SNA), but increased the PNA. In view of these demonstrated distinctive effects of ACh in different Available online 25 January 2017 subnuclei of the NTS the current studies were undertaken to examine, using patch clamp techniques, the specific effects of ACh on the excitability of individual neurons in the NTS, as well as the neuropharma- Keywords: cology of these actions. Coronal slices of the brainstem containing either cNTS or iNTS subnuclei were Nicotinic receptors used, and whole cell patch clamp recordings obtained from individual neurons in these two subnuclei. Muscarinic receptors Acetylcholine In cNTS, 58% of recorded neurons (n = 12) demonstrated rapid reversible depolarizations in response to Patch clamp ACh (10 mM), effects which were inhibited by the nicotinic antagonist mecamylamine (10 lM), but unaf- fected by the muscarinic antagonist atropine (10 lM). Similarly, bath application of ACh depolarized 76% of iNTS neurons (n = 17), although in this case both atropine and mecamylamine reduced the ACh- induced depolarization. These data demonstrate that ACh depolarizes cNTS neurons through actions on nicotinic receptors, while depolarizing effects in iNTS are apparently mediated by both receptors. Ó 2017 Elsevier B.V. All rights reserved. 1. Introduction a number of other neurotransmitters, such as dopamine, GABA, substance P, angiotensin II and acetylcholine (ACh), have been sug- The nucleus of the solitary tract (NTS) is an important medullary gested to contribute to the neurotransmission of cardiorespiratory area that receives peripheral afferent information from cardiovas- signals in the NTS (Abdala et al., 2006; Andresen and Kunze, 1994; cular and respiratory systems (Ciriello et al., 1994; Cottle, 1964; Criscione et al., 1983; da Silva et al., 2008; Furuya et al., 2014; Palkovits and Zaborsky, 1977). Baroreceptors make their first Sapru, 1996; Tsukamoto et al., 1994). Choline acetyltransferase synapse mainly at the level of the intermediate subnucleus of the positive neurons, high choline acetyltransferase and acetyl- NTS (iNTS; Ciriello et al., 1994), while peripheral chemoreceptors cholinesterase activity, muscarinic and nicotinic receptors are project primarily to the commissural subnucleus of the NTS (cNTS; found in the NTS (Cheng et al., 2011; Ernsberger et al., 1988; Ciriello et al., 1994). Functional data have demonstrated that lesions Gotts et al., 2015; Helke et al., 1983; Simon et al., 1981; Wada of the iNTS abolish the baroreflex, whereas cNTS lesions impair the et al., 1989). In fact, microinjection of ACh or the muscarinic ago- pressor and bradycardia induced by chemoreceptor activation, nist carbachol into the iNTS of anaesthetized or awake rats induces leaving the baroreflex unchanged (Blanch et al., 2013; Colombari dose-dependent baroreflex-like hypotensive and bradycardic et al., 1996; Miura and Reis, 1972; Schreihofer et al., 1999). responses (Criscione et al., 1983; da Silva et al., 2008; Tsukamoto Although L-glutamate has been proposed as the major excita- et al., 1994). Similar responses are also produced by nicotinic tory neurotransmitter released by the baro- and chemoreceptors receptor activation in the iNTS (Dhar et al., 2000). More recently, afferent inputs in the NTS (Machado, 2001; Talman et al., 1980), we have shown that the microinjection of ACh in the iNTS pro- duced sympatho-inhibitory responses and reduced phrenic fre- quency, whereas in cNTS microinjections of ACh did not change ⇑ Corresponding author at: Department of Physiology & Pathology, School of the sympathetic nerve activity (SNA), but increased the PNA Dentistry of Araraquara, UNESP Rua Humaitá, 1680, Araraquara 14801-903, SP, (Furuya et al., 2014). In this study, we also demonstrated that pre- Brazil. E-mail address: [email protected] (D.S.A. Colombari). treatment with mecamylamine (nicotinic antagonist) abolished all 1 DSAC and AVF are co-seniors. the effects of ACh injected into the iNTS or the cNTS, whereas http://dx.doi.org/10.1016/j.brainres.2017.01.027 0006-8993/Ó 2017 Elsevier B.V. All rights reserved. W.I. Furuya et al. / Brain Research 1659 (2017) 136–141 137 atropine (muscarinic antagonist) reduced only the effects of ACh ATR vs. 7.8 ± 2.4 mV after ATR, p < 0.05, n = 8) as illustrated in injected into the cNTS (Furuya et al., 2014). Fig. 4A and C). Similar recordings from ACh responsive iNTS neu- Cell recording studies have shown that ACh changes the current rons showed that mecamylamine (10 lM, 5 min), administration of NTS neurons. For instance, in medullary horizontal slices, ACh almost completely abolished the effects of a second application increases the firing frequency of iNTS neurons, and such effects of ACh on these neurons (9.5 ± 2.0 mV before MEC vs. are reduced by both muscarinic and nicotinic receptors blockade 2.9 ± 1.0 mV after MEC, p < 0.05, n = 8), as illustrated in (Shihara et al., 1999). In the same study, it was demonstrated that Fig. 4B and C. The cholinergic antagonists alone did not change muscarinic receptor activation inhibits K+ channels, while nicotinic the resting membrane potential of iNTS neurons. activation promotes Na+/K+ channels opening (Shihara et al., 1999; Shiraki et al., 1997). In another study, using NTS cell culture from 3. Discussion neonatal rats, it was found that both ACh and nicotine induced depolarizing current (Ueno et al., 1993). While these data demon- In the present study, we demonstrated, using whole cell patch strate that ACh depolarizes iNTS cells, resulting in increased firing clamp techniques, depolarizing effects of ACh on the majority of frequency, to date studies have not compared the effects of ACh on neurons recorded from NTS slices. These effects were observed in distinct NTS subnuclei. Given the different physiological responses both iNTS and cNTS and were found to be rapid, reversible and con- elicited by ACh in iNTS and cNTS, the present study was under- centration dependent. A significant proportion of NTS neurons taken to examine both the cellular effects and neuropharmacology were also found to be non-responsive, and it should be noted that of ACh in these NTS subnuclei. no hyperpolarizations were seen. The nicotinic receptor antagonist mecamylamine, inhibited the responses to ACh in both iNTS and 2. Results cNTS, suggesting roles for these receptors in both regions. In con- trast, the muscarinic antagonist atropine inhibits the ACh actions 2.1. Acetylcholine depolarizes cNTS neurons in the iNTS, but was without effect in the cNTS, suggesting a region-specific functional role for the muscarinic receptor in iNTS. We first examined the effects of 10 mM ACh (1 min bath perfu- Nicotinic and muscarinic receptors have been found in the NTS sion) on the membrane potential of 12 cNTS neurons. The majority (Cheng et al., 2011; Ernsberger et al., 1988; Gotts et al., 2015; Wada of these cells (7/12–58%) showed rapid, reversible depolarizations et al., 1989), although the differential localization within the cNTS (mean 6.9 ± 1.5 mV) as illustrated in Fig. 1C–E, while the remaining and iNTS of both receptors were not systematically studied using 5 neurons tested were unaffected. (-0.0 ± 0.7 mV). The 1.0 mM con- either immunohistochemical or receptor autoradiography proto- centration of ACh depolarized 2 out of 4 cNTS neurons, and the cols. In the present study, it was observed that in the cNTS, the magnitude of the depolarizations observed was smaller ACh evoked response was blocked by nicotinic receptors, while (4.5 ± 1.2 mV), (Fig. 1B, D-E). Finally, at a concentration of atropine did not change the depolarizing effect of ACh. In a previ- 0.1 mM ACh, no significant effects were observed on the mem- ous study using the in situ preparation, we have observed that ACh brane potential of 4 neurons tested (Fig. 1A, D-E). in the cNTS does not alter SNA, but increase the PNA and changed Next, we examined the ability of cholinergic antagonists to the sympatho-respiratory coupling (Furuya et al., 2014). In that modulate these depolarizing effects of ACh on cNTS neurons. In a study, at equimolar doses, atropine reduced and mecamylamine group of 7 neurons which showed clear depolarizing effects of blocked the tachypnea induced by ACh in the cNTS, whereas only ACh before bath administration of atropine (ATR; 10 lM, 5 min), the nicotinic receptor blockade was able to revert the change in responses to a subsequent similar administration of ACh were sympatho-respiratory coupling induced by ACh in the cNTS unaffected (7.6 ± 2.6 mV before ATR vs. 6.7 ± 1.9 mV after ATR, (Furuya et al., 2014) and to reduce the peripheral p > 0.05, n = 7) as illustrated in Fig. 2A and C. In 5 ACh responsive chemoreceptor-induced tachypnea (Furuya et al., 2014). Therefore, cNTS neurons mecamylamine (MEC; 10 lM, 5 min) administration even though in the in situ studies muscarinic receptors in the cNTS completely abolished the effects of a second application of ACh might have a role in mediating ACh-induced responses, it seems (10.4 ± 2.7 mV before MEC vs.
Recommended publications
  • Consumer Medicine Information
    New Zealand Datasheet Name of Medicine DOZILE Doxylamine Succinate 25 mg Capsules Presentation Liquid filled soft gel capsules, purple, containing 25 mg doxylamine succinate. Uses Actions Doxylamine succinate is a white or creamy white powder with a characteristic odour and has solubilities of approximately 1 g/mL in water and 500 mg/mL in alcohol at 25°C. It has a pKa of 5.8 and 9.3. A 1% aqueous solution has a pH of 4.8 - 5.2. Doxylamine succinate is an ethanolamine derivative antihistamine. Because of its sedative effect, it is used for the temporary relief of sleeplessness. The drug is also used in combination with antitussives and decongestants for the temporary relief of cold and cough symptoms. It is not structurally related to the cyclic antidepressants. It is an antihistamine with hypnotic, anticholinergic, antimuscarinic and local anaesthetic effects. Duration of action is 6-8 hours. Pharmacokinetics Following oral administration of a single 25 mg dose of doxylamine succinate in healthy adults, mean peak plasma concentrations of about 100 ng/mL occur within 2- 3 hours after administration. The drug has an elimination half-life of about 10 hours in healthy adults. Absorption It is easily absorbed from the gastrointestinal tract. Following an oral dose of 25 mg the mean peak plasma level is 99 ng/mL 2.4 hours after ingestion. This level declines to 28 ng/mL at 24 hours and 10 ng/mL at 36 hours. Distribution The apparent volume of distribution is 2.5 L/kg. Metabolism The major metabolic pathways are N-demethylation, N-oxidation, hydroxylation, N- acetylation, N-desalkylation and ether cleavage.
    [Show full text]
  • Severe Organophosphate Poisoning with Delayed Cholinergic Crisis, Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy on Succession
    Organophosphate Poisoning… Aklilu A 203 CASE REPORT SEVERE ORGANOPHOSPHATE POISONING WITH DELAYED CHOLINERGIC CRISIS, INTERMEDIATE SYNDROME AND ORGANOPHOSPHATE INDUCED DELAYED POLYNEUROPATHY ON SUCCESSION Aklilu Azazh ABSTRACT Organophosphate compounds are the organic derivatives of Phosphorous containing acids and their effect on neuromuscular junction and Autonomic Synapses is clinically important. After exposure these agents cause acute and sub acute manifestations depending on the type and severity of the agents like Acute Cholinergic Manifestations, Intermediate Syndrome with Nicotinic features and Delayed Central Nervous System Complications. The patient reported here had severe Organophosphate Poisoning with various rare complications on a succession. This is the first report of Organophosphates Poisoning complicated by Intermediate Syndrome and Organophosphate Induced Delayed Polyneuropathy in Ethiopia and it is reported to increase awareness of health care workers on these rare complications of a common problem. INTRODUCTION phosphorylated by the Phosphate end of Organophosphates; then the net result is Organophosphate compounds are the organic accumulation of excessive Acetyl Chlorine with derivatives of Phosphorous containing acids and resultant effect on Muscarinic, Nicotinic and their effect on Neuromuscular Junction and central nervous system (Figure 2). Autonomic synapses is clinically important. In the Neuromuscular Junction Acetylcholine is released Following classical OP poisoning, three well when a nerve impulse reaches
    [Show full text]
  • Effects of the Nicotinic Agonist Varenicline, Nicotinic Antagonist R-Bpidi, and DAT Inhibitor R-Modafinil on Co-Use of Ethanol and Nicotine in Female P Rats
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Psychopharmacology Manuscript Author (Berl) Manuscript Author . Author manuscript; available in PMC 2019 May 01. Published in final edited form as: Psychopharmacology (Berl). 2018 May ; 235(5): 1439–1453. doi:10.1007/s00213-018-4853-4. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor R-modafinil on co-use of ethanol and nicotine in female P rats. Sarah E. Maggio1, Meredith A. Saunders1, Thomas A. Baxter1, Kimberly Nixon2, Mark A. Prendergast1, Guangrong Zheng3, Peter Crooks3, Linda P. Dwoskin2, Rachel D. Slack4, Amy H. Newman4, Richard L. Bell5, and Michael T. Bardo1 1Department of Psychology, University of Kentucky, Lexington, KY 40536, USA. 2Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA. 3Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas, Little Rock, AR 72205, USA. 4Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse- Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, USA. 5Department of Psychiatry, Institute of Psychiatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Abstract Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15%, 2-bottle choice); (2) nicotine alone (0.03 mg/kg/infusion, active vs.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Protocol for a Randomised Controlled Trial: Efficacy of Donepezil Against
    BMJ Open: first published as 10.1136/bmjopen-2013-003533 on 25 September 2013. Downloaded from Open Access Protocol Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP) Hideyuki Sawada, Tomoko Oeda To cite: Sawada H, Oeda T. ABSTRACT ARTICLE SUMMARY Protocol for a randomised Introduction: Psychosis, including hallucinations and controlled trial: efficacy of delusions, is one of the important non-motor problems donepezil against psychosis Strengths and limitations of this study in patients with Parkinson’s disease (PD) and is in Parkinson’s disease ▪ In previous randomised controlled trials for (EDAP). BMJ Open 2013;3: possibly associated with cholinergic neuronal psychosis the efficacy was investigated in patients e003533. doi:10.1136/ degeneration. The EDAP (Efficacy of Donepezil against who presented with psychosis and the primary bmjopen-2013-003533 Psychosis in PD) study will evaluate the efficacy of endpoint was improvement of psychotic symp- donepezil, a brain acetylcholine esterase inhibitor, for toms. By comparison, this study is designed to prevention of psychosis in PD. ▸ Prepublication history for evaluate the prophylactic effect in patients this paper is available online. Methods and analysis: Psychosis is assessed every without current psychosis. Because psychosis To view these files please 4 weeks using the Parkinson Psychosis Questionnaire may be overlooked and underestimated it is visit the journal online (PPQ) and patients with PD whose PPQ-B score assessed using a questionnaire, Parkinson (http://dx.doi.org/10.1136/ (hallucinations) and PPQ-C score (delusions) have Psychosis Questionnaire (PPQ) every 4 weeks. bmjopen-2013-003533). been zero for 8 weeks before enrolment are ▪ The strength of this study is its prospective randomised to two arms: patients receiving donepezil design using the preset definition of psychosis Received 3 July 2013 hydrochloride or patients receiving placebo.
    [Show full text]
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • PRESCRIBING INFORMATION (Dicyclomine Hydrochloride USP
    PRESCRIBING INFORMATION BENTYLOL® (dicyclomine hydrochloride USP) Tablets 10 mg and 20 mg Syrup 10 mg/5 mL Antispasmodic APTALIS PHARMA CANADA INC. Date of Revision: 597 Laurier Blvd. July 16, 2012 Mont-St-Hilaire, Quebec J3H 6C4 Control number: 156699 BENTYLOL® (dicyclomine hydrochloride, USP) Prescribing Information Tablets & Syrup PRESCRIBING INFORMATION BENTYLOL® (dicyclomine hydrochloride USP) 10 mg and 20 mg Tablets Syrup, 10 mg/5 mL Antispasmodic ACTION AND CLINICAL PHARMACOLOGY Bentylol (dicyclomine) relieves smooth muscle spasm of the gastrointestinal tract. Animal studies indicate that this action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine (ACh)-receptor sites with approximately 1/8 the milligram potency of atropine (in vitro guinea pig ileum); and (2) a direct effect upon smooth muscle (musculotropic) as evidenced by dicyclomine's antagonism of bradykinin- and histamine-induced spasms of the isolated guinea pig ileum. Atropine did not affect responses to these two agonists. Animal studies showed dicyclomine to be equally potent against ACh - or barium chloride (BaCl2) - induced intestinal spasm while atropine was at least 200 times more potent against the effects of ACh than against BaCl2. Tests for mydriatic effects in mice showed that dicyclomine was approximately 1/500 as potent as atropine; antisialagogue tests in rabbits showed dicyclomine to be 1/300 as potent as atropine. After a single oral 20 mg dose of dicyclomine in volunteers, peak plasma concentration reached a mean value of 58 ng/mL in 1 to 1.5 hours. The principal route of elimination is via the urine. __________________________________________________________________________________ Aptalis Pharma Canada Inc.
    [Show full text]
  • Viewed the Existence of Multiple Muscarinic CNS Penetration May Occur When the Blood-Brain Barrier Receptors in the Mammalian Myocardium and Have Is Compromised
    BMC Pharmacology BioMed Central Research article Open Access In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine G Howell III†1, L West†1, C Jenkins2, B Lineberry1, D Yokum1 and R Rockhold*1 Address: 1Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA and 2Tougaloo College, Tougaloo, MS, USA Email: G Howell - [email protected]; L West - [email protected]; C Jenkins - [email protected]; B Lineberry - [email protected]; D Yokum - [email protected]; R Rockhold* - [email protected] * Corresponding author †Equal contributors Published: 18 August 2005 Received: 06 October 2004 Accepted: 18 August 2005 BMC Pharmacology 2005, 5:13 doi:10.1186/1471-2210-5-13 This article is available from: http://www.biomedcentral.com/1471-2210/5/13 © 2005 Howell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation antihistamines which effectively antagonize the H1 receptor without significant affinity for muscarinic receptors have been developed. However, both in vitro and in vivo experimentation indicates that the third generation antihistamine, desloratadine, antagonizes muscarinic receptors. To fully examine the in vivo antimuscarinic efficacy of desloratadine, two murine and two rat models were utilized. The murine models sought to determine the efficacy of desloratadine to antagonize muscarinic agonist induced salivation, lacrimation, and tremor.
    [Show full text]
  • Drugs to Avoid in Patients with Dementia
    Detail-Document #240510 -This Detail-Document accompanies the related article published in- PHARMACIST’S LETTER / PRESCRIBER’S LETTER May 2008 ~ Volume 24 ~ Number 240510 Drugs To Avoid in Patients with Dementia Elderly people with dementia often tolerate drugs less favorably than healthy older adults. Reasons include increased sensitivity to certain side effects, difficulty with adhering to drug regimens, and decreased ability to recognize and report adverse events. Elderly adults with dementia are also more prone than healthy older persons to develop drug-induced cognitive impairment.1 Medications with strong anticholinergic (AC) side effects, such as sedating antihistamines, are well- known for causing acute cognitive impairment in people with dementia.1-3 Anticholinergic-like effects, such as urinary retention and dry mouth, have also been identified in drugs not typically associated with major AC side effects (e.g., narcotics, benzodiazepines).3 These drugs are also important causes of acute confusional states. Factors that may determine whether a patient will develop cognitive impairment when exposed to ACs include: 1) total AC load (determined by number of AC drugs and dose of agents utilized), 2) baseline cognitive function, and 3) individual patient pharmacodynamic and pharmacokinetic features (e.g., renal/hepatic function).1 Evidence suggests that impairment of cholinergic transmission plays a key role in the development of Alzheimer’s dementia. Thus, the development of the cholinesterase inhibitors (CIs). When used appropriately, the CIs (donepezil [Aricept], rivastigmine [Exelon], and galantamine [Razadyne, Reminyl in Canada]) may slow the decline of cognitive and functional impairment in people with dementia. In order to achieve maximum therapeutic effect, they ideally should not be used in combination with ACs, agents known to have an opposing mechanism of action.1,2 Roe et al studied AC use in 836 elderly patients.1 Use of ACs was found to be greater in patients with probable dementia than healthy older adults (33% vs.
    [Show full text]
  • Diphenhydramine Hydrochloride Oral Solution USP Rx ONLY
    DIPHENHYDRAMINE HYDROCHLORIDE- diphenhydramine hydrochloride solution Pharmaceutical Associates, Inc. ---------- Diphenhydramine Hydrochloride Oral Solution USP Rx ONLY DESCRIPTION Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2- (diphenylmethoxy)-N,N -dimethylethylamine hydrochloride and has the molecular formula C 17H 21NO•HCI (molecular weight 291.82). It occurs as a white odorless, crystalline powder and is freely soluble in water and alcohol. The structural formula is as follows: Each 5 mL contains 12.5 mg of diphenhydramine hydrochloride and alcohol 14% for oral administration. Inactive Ingredients: Citric acid, D&C Red No. 33, FD&C Red No. 40, flavoring, purified water, sodium citrate, and sucrose. CLINICAL PHARMACOLOGY Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells. A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. Diphenhydramine is widely distributed throughout the body, including the CNS. Little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours. INDICATIONS AND USAGE Diphenhydramine hydrochloride in the oral form is effective for the following indications: Antihistaminic For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.
    [Show full text]
  • The Role of Serotonin in Memory: Interactions with Neurotransmitters and Downstream Signaling
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bushehr University of Medical Sciences Repository Exp Brain Res (2014) 232:723–738 DOI 10.1007/s00221-013-3818-4 REVIEW The role of serotonin in memory: interactions with neurotransmitters and downstream signaling Mohammad Seyedabadi · Gohar Fakhfouri · Vahid Ramezani · Shahram Ejtemaei Mehr · Reza Rahimian Received: 28 April 2013 / Accepted: 20 December 2013 / Published online: 16 January 2014 © Springer-Verlag Berlin Heidelberg 2014 Abstract Serotonin, or 5-hydroxytryptamine (5-HT), is there has been an alteration in the density of serotonergic found to be involved in many physiological or pathophysi- receptors in aging and Alzheimer’s disease, and serotonin ological processes including cognitive function. Seven dis- modulators are found to alter the process of amyloidogen- tinct receptors (5-HT1–7), each with several subpopulations, esis and exert cognitive-enhancing properties. Here, we dis- have been identified for serotonin, which are different in cuss the serotonin-induced modulation of various systems terms of localization and downstream signaling. Because involved in mnesic function including cholinergic, dopa- of the development of selective agonists and antagonists minergic, GABAergic, glutamatergic transmissions as well for these receptors as well as transgenic animal models as amyloidogenesis and intracellular pathways. of cognitive disorders, our understanding of the role of serotonergic transmission in learning and memory has Keywords Serotonin · Memory · Signaling pathways improved in recent years. A large body of evidence indi- cates the interplay between serotonergic transmission and Abbreviations other neurotransmitters including acetylcholine, dopamine, 2PSDT Two-platform spatial discrimination task γ-aminobutyric acid (GABA) and glutamate, in the neu- 3xTg-AD Triple-transgenic mouse model of Alzheimer’s robiological control of learning and memory.
    [Show full text]
  • Cognitive, Behavioral, and Physiologic Responses John T
    Combined Nicotinic and Muscarinic Blockade in Elderly Normal Volunteers: Cognitive, Behavioral, and Physiologic Responses John T. Little, M.D., Douglas N. Johnson, Ph.D., Marcia Minichiello, M.A., Herb Weingartner, Ph.D., and Trey Sunderland, M.D. Establishing a pharmacologic model of the memory deficits scopolamine alone. Increased impairment was also seen for of Alzheimer’s disease could be an important tool in the mecamylamine 1 scopolamine condition as compared to understanding how memory fails. We examined the scopolamine alone in selected behavioral ratings. Pupil size combined effects of the muscarinic antagonist scopolamine increased when mecamylamine was added to scopolamine, and the nicotinic antagonist mecamylamine in eight normal while systolic blood pressure and pulse changed in elderly volunteers (age 61.9 6 8.3 yrs, SD). Each received concordance with ganglionic blockade. These data together four separate drug challenges (scopolamine (0.4 mg IV), with previous brain-imaging results suggest that this mecamylamine (0.2 mg/kg up to 15 mg PO), muscarinic–nicotinic drug combination may better model mecamylamine 1 scopolamine, and placebo). There was a Alzheimer’s disease than either drug alone. trend toward increased impairment in explicit memory for [Neuropsychopharmacology 19:60–69, 1998] the mecamylamine 1 scopolamine condition as compared to Published by Elsevier Science Inc. KEY WORDS: Scopolamine; Mecamylamine; Cognitive; al. 1985; Shimohama et al. 1986; Whitehouse and Au Geriatrics; Muscarinic antagonist; Nicotinic antagonist 1986; D’Amato et al. 1987; Zubenko et al. 1988), many cognitive dysfunction modeling studies have focused Given the limited animal models of Alzheimer’s disease on this system (Beatty et al.
    [Show full text]